Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

February 24, 2026

WATERTOWN, Mass., February 24, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)

August 21, 2026

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc.,... Read More

July 31, 2026

Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

WATERTOWN, Mass., July 31, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

May 7, 2026

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

WATERTOWN, Mass., May 7, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

Share this article: